文献速递银屑病与炎症性皮肤病

SYSA1902与参照乌司奴单抗治疗中重度斑块状银屑病的疗效与安全性

Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: A multicenter, randomized, phase III study.
PubMed 文献 · J Am Acad Dermatol · 2025-04-10

这项多中心随机III期研究纳入446例中重度斑块状银屑病患者,比较生物类似药SYSA1902与参照乌司奴单抗(Stelara)45 mg皮下注射的疗效与安全性。第12周PASI较基线平均改善率分别为86.4%和84.7%,差异1.68%(95%CI -1.45至4.81),落在±15%等效界值内。结论为SYSA1902与乌司奴单抗等效。

要点

  • 第12周PASI改善率差异1.68%(95%CI -1.45至4.81),在±15%等效界值内
  • 第12周PASI 75:SYSA1902组83.3%,乌司奴单抗组79.3%
  • 总体治疗中出现的不良事件率分别为89.3%和85.6%,多为轻中度,上呼吸道感染最常见

核心结论

  • SYSA1902在治疗中重度斑块状银屑病方面与乌司奴单抗等效。

研究设计与样本

  • 多中心、随机、III期研究,共446例患者随机分配至SYSA1902组(n=224)和乌司奴单抗组(n=222)。
  • 给药方案为第0、4、16、28、40周皮下注射45 mg。
  • 主要终点为第12周PASI较基线改善百分比,等效界值为差值95%CI在±15%以内。

主要发现

  • 第12周PASI较基线平均改善率:SYSA1902组86.4%,乌司奴单抗组84.7%,差异1.68%(95%CI -1.45至4.81)。
  • 第12周达到PASI 75者:SYSA1902组185例(83.3%),乌司奴单抗组172例(79.3%)。
  • 总体治疗中出现的不良事件率:SYSA1902组89.3%,乌司奴单抗组85.6%,多为轻中度,上呼吸道感染最常见。

关键数值与推荐

  • 等效判定标准:主要终点差值的95%CI需落在±15%界值内,本研究结果满足该标准。
  • 主要终点:第12周PASI较基线改善百分比。

临床怎么用

  • 结果支持SYSA1902作为乌司奴单抗的生物类似药用于中重度斑块状银屑病。
  • 用药方案为45 mg皮下注射,于第0、4、16、28、40周给药。

局限性

  • 数据仅限中国患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SYSA1902 is a biosimilar of ustekinumab. OBJECTIVE: Evaluate the efficacy and safety of SYSA1902 compared with reference ustekinumab in patients with moderate-to-severe plaque psoriasis. METHODS: Eligible patients were randomized to receive SYSA1902 or ustekinumab (Stelara, Janssen) 45 mg subcutaneously at week 0, 4, 16, 28, and 40. The primary end point was the percentage improvement from baseline in psoriasis area and severity index (PASI) at week 12. Equivalence was verified if the 95% CI of difference was within ± 15%. RESULTS: A Total of 446 patients were assigned to SYSA1902 (n = 224) and ustekinumab groups (n = 222). At week 12, the mean percentage change from baseline in PASI was 86.4% in the SYSA1902 group and 84.7% in the ustekinumab group, with a difference of 1.68% (95% CI, -1.45 to 4.81), which fell within the equivalence margins. PASI 75 at week 12 was achieved by 185 (83.3%) of patients receiving SYSA1902 versus 172 (79.3%) receiving ustekinumab. Overall treatment-emergent adverse events rate was 89.3% and 85.6% in the SYSA1902 and ustekinumab groups. Most treatment-emergent adverse events were mild to moderate, with upper respiratory tract infection being the most common. LIMITATIONS: Data limited to Chinese patients. CONCLUSION: SYSA1902 is equivalent to ustekinumab for the treatment of moderate-to-severe plaque psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Xia L, Miao G, Yang X, et al. Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: A multicenter, randomized, phase III study. J Am Acad Dermatol. 2025. PMID: 40208132. doi:10.1016/j.jaad.2025.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。